Responses
Rheumatoid arthritis
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Compose a Response to This Article
Other responses
No responses have been published for this article.